Home » Stocks » HJLI

Hancock Jaffe Laboratories, Inc. (HJLI)

Stock Price: $8.54 USD -0.55 (-6.05%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $9.20 +0.66 (7.73%) Jan 15, 7:59 PM
Market Cap 19.08M
Revenue (ttm) n/a
Net Income (ttm) -7.08M
Shares Out 1.45M
EPS (ttm) -7.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $8.54
Previous Close $9.09
Change ($) -0.55
Change (%) -6.05%
Day's Open 9.05
Day's Range 8.26 - 9.01
Day's Volume 286,388
52-Week Range 6.75 - 18.81

News

There are no news available yet.

About HJLI

Hancock Jaffe Laboratories, a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to... [Read more...]

Industry
Medical Devices
Founded
1987
CEO
Robert A. Berman
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
HJLI
Full Company Profile

Financial Performance

In 2019, HJLI's revenue was $31,243, a decrease of -83.25% compared to the previous year's $186,552. Losses were -$7.63 million, -41.54% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for HJLI stock is "Strong Buy" and the 12-month stock price forecast is 26.25.

Price Target
$26.25
Analyst Consensus: Strong Buy